Brian Andrew Jonas

NCI R50 Clinician Scientist Award

National Cancer Institute · R50

Contact PI · $348.6K · University of California at Davis

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

Principal investigator · Recruiting · Phase 2

University of California, Davis

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Principal investigator · Recruiting · Phase 2

Brian Jonas

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Principal investigator · Terminated · Phase 1

Brian Jonas

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Principal investigator · Active not recruiting · Phase 1

National Cancer Institute (NCI)